Pushkal Garg Alnylam Pharmaceuticals, Inc. (ALNY) insider trading activity

Pushkal Garg is CMO & EVP Dev & Med Affairs of ALNYLAM PHARMACEUTICALS, INC.. Currently has a direct ownership of 20,221 shares of ALNY, which is worth approximately $5.43 Million. The most recent transaction as insider was on Mar 24, 2025, when has been sold 5,445 shares (Common Stock) at a price of $300.0 per share, resulting in proceeds of $1,633,500. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 20.2K

28.76% 3M change

50.71% 12M change

Total Value Held $5.43 Million

Pushkal Garg Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Mar 24 2025	SELL Open market or private sale	$1,633,500 $300.0 p/Share	5,445 Reduced 21.21%	20,221 Common Stock
Mar 24 2025	BUY Exercise of conversion of derivative security	$229,887 $42.22 p/Share	5,445 Added 17.5%	25,666 Common Stock
Mar 21 2025	SELL Open market or private sale	$1,231,485 $285.0 p/Share	4,321 Reduced 17.61%	20,221 Common Stock
Mar 04 2025	SELL Open market or private sale	$194,824 $241.12 p/Share	808 Reduced 3.19%	24,542 Common Stock
Mar 03 2025	SELL Open market or private sale	$428,574 $245.04 p/Share	1,749 Reduced 6.45%	25,350 Common Stock
Mar 03 2025	BUY Grant, award, or other acquisition	-	14,137 Added 34.28%	27,099 Common Stock
Feb 28 2025	SELL Open market or private sale	$225,054 $240.7 p/Share	935 Reduced 6.73%	12,962 Common Stock
Feb 27 2025	BUY Exercise of conversion of derivative security	-	1,908 Added 12.07%	13,897 Common Stock
Feb 18 2025	SELL Open market or private sale	$393,594 $254.26 p/Share	1,548 Reduced 11.44%	11,989 Common Stock
Feb 14 2025	SELL Open market or private sale	$402,940 $258.13 p/Share	1,561 Reduced 10.34%	13,537 Common Stock
Feb 13 2025	BUY Grant, award, or other acquisition	-	3,109 Added 17.08%	15,098 Common Stock
Jan 27 2025	SELL Open market or private sale	$14,988,720 $285.0 p/Share	52,592 Reduced 81.44%	11,989 Common Stock
Jan 27 2025	BUY Exercise of conversion of derivative security	$4,347,520 $88.95 p/Share	48,876 Added 43.08%	64,581 Common Stock
Dec 12 2024	SELL Open market or private sale	$440,838 $251.62 p/Share	1,752 Reduced 10.04%	15,705 Common Stock
Nov 26 2024	SELL Open market or private sale	$421,088 $250.35 p/Share	1,682 Reduced 8.79%	17,457 Common Stock
Nov 25 2024	BUY Grant, award, or other acquisition	-	3,434 Added 15.21%	19,139 Common Stock
Oct 08 2024	BUY Grant, award, or other acquisition	-	96 Added 0.61%	15,705 Common Stock
Jun 25 2024	SELL Open market or private sale	$482,470 $229.42 p/Share	2,103 Reduced 11.87%	15,609 Common Stock
Jun 24 2024	BUY Grant, award, or other acquisition	-	4,295 Added 19.52%	17,712 Common Stock
Mar 01 2024	BUY Grant, award, or other acquisition	-	4,751 Added 26.15%	13,417 Common Stock
Feb 28 2024	SELL Open market or private sale	$89,744 $156.35 p/Share	574 Reduced 6.21%	8,666 Common Stock
Feb 27 2024	BUY Exercise of conversion of derivative security	-	1,908 Added 17.12%	9,240 Common Stock
Feb 16 2024	SELL Open market or private sale	$193,924 $148.26 p/Share	1,308 Reduced 15.14%	7,332 Common Stock
Feb 15 2024	BUY Grant, award, or other acquisition	-	4,295 Added 33.2%	8,640 Common Stock
Aug 07 2023	SELL Open market or private sale	$768,710 $184.52 p/Share	4,166 Reduced 48.95%	4,345 Common Stock

Also insider at

SQZ

SQZ Biotechnologies Co Healthcare

Director

Pushkal Garg

CMO & EVP Dev & Med Affairs

Cambridge, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ALNY shares.

Notify only if

Value

Insider Trading

Get notified when an Alnylam Pharmaceuticals, Inc. insider buys or sells ALNY shares.

Notify only if

Operation

Value

Type

News

Receive news related to ALNYLAM PHARMACEUTICALS, INC.

Track Activities on ALNY

Account